Robert Clair Kane

  • Citations Per Year
Learn More
A 43-year-old female with multiple sclerosis developed urethral melanoma. The only potential risk factor was treatment with natalizumab, a humanized monoclonal antibody against α4 integrins. To investigate the risk-exposure relationship, we reviewed this case, all other published cases, and cases of natalizumab-associated melanoma reported to regulatory(More)
Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the safety of this class of drugs. In this Series paper, we review clinical, policy, safety, and regulatory considerations for generic oncology drugs focusing on the USA, Canada, the European Union (EU), Japan,(More)
TO THE EDITOR: I found Delitto and colleagues' article (1) at odds with not only my experience but that of other published studies. The way that the data and results were reported leaves more questions than answers. The authors do not state whether the 169 patients who were deemed eligible for surgery had physical therapy (PT) first. If not, the 87 patients(More)
BACKGROUND When oral iron replacement therapy is ineffective, IV or IM iron dextran products have been used successfully in many patients. However, adverse events, including urticaria, anaphylaxis, and death, sometimes are associated with the use of these products. OBJECTIVE The aim of this study was to assess the efficacy and tolerability of sodium(More)
  • 1